2022: Year in Review

Myeloma Patients Europe’s (MPE) 2022 Year in Review is snapshot of the major accomplishments from the past year. In this report, you’ll read about MPE’s activities and key accomplishments to empower our members, educate the patient community, shape drug development, address gaps in patient evidence, and increase access to innovative treatments. We look forward to the continued growth and evolution of these initiatives in the years ahead as we continue our efforts to improve patient treatment, care,…

Talquetamab generates high response rate in patients with hard-to-treat myeloma

NEW ORLEANS. New research being presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition focuses on talquetamab in patients with Relapsed/Refractory myeloma. In an early-phase trial, nearly three-quarters of patients who received talquetamab, a first-in-class experimental immunotherapy for myeloma, saw a significant reduction in cancer burden within a few months. The study participants had all been previously treated with at least three different therapies without achieving lasting remission, suggesting talquetamab could offer new…

Horizon Europe research project looks to improve the affordability and sustainability of innovative health technologies

  Starting in December 2022, the HORIZON-funded project ASCERTAIN (Affordability and Sustainability improvements through new pricing, Cost- Effectiveness and Reimbursement models to Appraise innovative health technologies) will address the need of patients, physicians, payers, regulators, and manufacturers to improve the affordability and accessibility to innovative health technologies (including pharmaceuticals) in Europe. Affording newly approved innovative health technologies (IHTs) is challenging in many health systems.

Join MPE’s webinar on Access Barriers to Clinical Trials in CEE Countries

Myeloma Patient Europe (MPE) has been aware of the lack of clinical trials opening in many Central and Eastern European (CEE) countries, as well as inequalities in access with CEE countries for participating in ongoing trials. To gather data on, and further understand the access situation, MPE conducted research on barriers and facilitators to clinical trials, with a specific focus on CEE countries. The research was completed under the guidance of MPE members from across the region through its CEE…

Myeloma diagnosis can take over 5 months and require more than 4 medical consultations with more than 3 different specialists

Brussels, 27 September 2022 – For some European myeloma patients, their diagnosis can take over 5 months, require more than 4 medical consultations and involve visits to at least 3 different medical specialists. These are some of the findings of pan-European research conducted by Myeloma Patients Europe (MPE) with the aim of exploring patient and doctor (haematologist) experiences of myeloma diagnosis. MPE ran a survey, and several focus groups and interviews, in which more than 600…

The European Medicines Agency (EMA) approves Melflufen (Pepaxti®) for the treatment of refractory myeloma

  The European Commission has approved marketing authorisation (e.g. a license) for melphalan flufenamide (also called melflufen), a drug marketed in Europe by Oncopeptides with the name of Pepaxti®. This follows the previous positive recommendation from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP).